Clinical Trials on Immunodeficiency

Total 2287 results

Octapharma

Completed

A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push

Primary Immunodeficiency

United Kingdom, Australia, Germany, Italy
Ottawa Hospital Research Institute
Octapharma

Unknown

Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment

Primary Immunodeficiency Disease | Secondary Immunodeficiency

Canada
CSL Behring

Completed

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Primary Immunodeficiency (PID)

Poland, Germany, France, Romania, Spain, Sweden, Switzerland, United Kingdom
Oslo University Hospital

Completed

The Rifaximin Study in CVID

Common Variable Immunodeficiency (CVID)

Norway
National Cancer Institute (NCI)

Completed

Breadth of Donor Options for People With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide

Common Variable Immunodeficiency | Primary T-cell Immunodeficiency Disorders

United States
CSL Limited

Completed

Subcutaneous Ig NextGen 16% in PID Patients

Primary Immunodeficiency (PID)

Australia, New Zealand
National Cancer Institute (NCI)

Recruiting

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

Immune System Diseases | Lymphoproliferative Disorders | Common Variable Immunodeficiency | Primary T-cell Immunodeficiency Disorders | Autoimmune Lymphoproliferative

United States
Great Ormond Street Hospital for Children NHS Foundation...

Unknown

Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1)

X-linked Severe Combined Immunodeficiency

United Kingdom
Ospedale Policlinico San Martino
GlaxoSmithKline

Completed

Safety, Tolerability and Immunogenicity of 4CMenB Vaccine(2 Doses) in Adults With an Immunodeficiency (4CMenB)

Acquired Immunodeficiency

Italy
Technische Universität Dresden
GWT-TUD GmbH

Completed

Assessment of Immunoglobulins (IgG) in a Long-term Non-interventional Study (SIGNS)

Primary Immunodeficiency (PID) | Secondary Immunodeficiency (SID) | Neurological Autoimmune Disease

Germany
Octapharma

Completed

CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL

Primary Immunodeficiency

United States, Canada
Assiut University

Completed

Minipooled-IVIG in Primary Immunodeficiency Disease

Primary Immunodeficiency

Egypt
CSL Behring

Completed

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

Primary Immunodeficiency

United States, Canada
IMMUNOe Research Centers

Completed

The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations

Primary Immunodeficiency
Grifols Therapeutics LLC

Completed

Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency (KIDS)

Primary Immunodeficiency

United States
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine

Terminated

Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders (MASCI)

Severe Combined Immunodeficiency Disease | Severe Primary Immunodeficiency Disorder | Undefined T Cell Deficiency Disorder | Wiskott-Aldrick Syndrome

United States
Octapharma

Completed

Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps

Primary Immunodeficiency (PID)

France
University of California, Los Angeles
Jeffrey Modell Foundation

Unknown

Improving the Diagnosis of Common Variable Immune Deficiency

CVI - Common Variable Immunodeficiency

United States
Gazi University

Recruiting

Investigation of the Effects of Pulmonary Rehabilitation in Children With Primary Immunodeficiency

Primary Immunodeficiency

Turkey
Grifols Therapeutics LLC

Completed

A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency

Primary Immunodeficiency

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy of CDZ173 in Patients With APDS/PASLI

Common Variable Immunodeficiency (CVID), APDS / PASLI

Germany, Russian Federation, Ireland, Italy, United Kingdom, Belarus, Netherlands, Czechia, United States
Grifols Therapeutics LLC

Completed

Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency

Primary Immunodeficiency

United States, Canada
National Institute of Allergy and Infectious Diseases...

Recruiting

Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

X-linked Severe Combined Immunodeficiency (XSCID)

United States
St. Jude Children's Research Hospital
National Heart, Lung, and Blood Institute (NHLBI); Assisi Foundation; California...

Suspended

Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants (LVXSCID-ND)

Severe Combined Immunodeficiency Disease, X-linked

United States
Assistance Publique - Hôpitaux de Paris

Completed

Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID2)

X-linked Severe Combined Immunodeficiency

France
Takeda

Completed

An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease

Primary Immunodeficiency Disease

Japan
Grifols Therapeutics LLC

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency

Primary Immunodeficiency

United States
Octapharma

Completed

High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam) (NGAM-05)

Primary Immunodeficiency Disease

United States
Azidus Brasil
Boya Bio Pharmaceutical Group Co Ltd

Not yet recruiting

Efficacy and Safety and Pharmacokinetics of Boya IVIG (Boya)

Primary Immunodeficiency Disease
Azidus Brasil
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

Not yet recruiting

Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG (Imunoforte)

Primary Immunodeficiency Disease
University of Zurich
University Hospital, Geneva; University of Lausanne; University of Bern; University... and other collaborators

Unknown

Clinical and Laboratory Online Patient- and Research Database for Primary Immunodeficiencies in Switzerland

Primary Immunodeficiency Disease

Switzerland
Ann & Robert H Lurie Children's Hospital of Chicago

Unknown

Early Diagnosis and Stem Cell Transplantation for Severe Immunodeficiency Diseases (SIDS)

Severe Immunodeficiency Diseases

United States
CHU de Reims

Unknown

Tolerance and Patients' Satisfaction With IGHy

Secondary or Primary Immunodeficiency

France
Merck Sharp & Dohme LLC

Withdrawn

MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002)

HIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
National Institute of Allergy and Infectious Diseases...

Recruiting

Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies

Primary Immunodeficiency

United States, Turkey, Italy
Prometic Biotherapeutics, Inc.
Atlantic Research Group

Completed

Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%

Primary Immunodeficiency

United States
Grifols Therapeutics LLC

Completed

Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency

Primary Immunodeficiency

Spain, France, Germany, United Kingdom, Australia, Czechia, Hungary, Poland, Sweden
University Hospital, Lille
Shire

Completed

IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia

Primary Immunodeficiency

France
ASIS Corporation

Unknown

ASIS for GAMMAGARD in Primary Immunodeficiency (ASISinPI)

Primary Immunodeficiency

United States
Great Ormond Street Hospital for Children NHS Foundation...

Recruiting

Lentiviral Gene Therapy for X-linked Severe Combined Immunodeficiency

Severe Combined Immunodeficiency, X-Linked

United Kingdom
Shenzhen Geno-Immune Medical Institute

Unknown

Gene Transfer for ADA-SCID Using an Improved Lentiviral Vector (TYF-ADA)

Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)

China
Takeda

Active, not recruiting

A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants

Primary Immunodeficiency Diseases (PID)

Japan
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Gammagard Liquid and rHuPH20 in PID

Primary Immunodeficiency Diseases (PID)

United States, Canada
Baxalta now part of Shire

Completed

Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID

Primary Immunodeficiency Diseases (PID)

United States
BriovaRx Infusion Services
Bio Products Laboratory (BPL)

Completed

Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting

Primary Immunodeficiency Disease (PIDD)

United States
Federal Research Institute of Pediatric Hematology...

Recruiting

Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies

Primary Immunodeficiency Diseases (PID)

Russian Federation
Baxalta now part of Shire

Completed

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

Primary Immunodeficiency Diseases (PID)

United States

Clinical Trials on Immunodeficiency

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations